DDS vs MUSA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
DDS exhibits exceptional financial health with a Piotroski F-Score of 8/9 and a very low Debt/Equity ratio of 0.31. However, the stock is significantly overvalued, trading at $595.20—nearly double its Graham Number ($305.57) and Intrinsic Value ($255.01). While profitability remains high with an ROE of 31.90%, the company is facing a growth stagnation with negative YoY revenue and earnings growth. The disconnect between strong fundamental health and poor valuation/growth metrics suggests a limited upside from current levels.
MUSA presents a dichotomy of high operational efficiency and precarious financial health. While the Piotroski F-Score of 4/9 indicates stable but mediocre health, the company's extreme leverage (Debt/Equity 4.40) and poor liquidity (Current Ratio 0.81) are significant concerns. The stock trades at a substantial premium to its Graham Number ($134.89) and slightly above its intrinsic value ($461.13), suggesting a valuation driven by high ROE rather than fundamental asset backing. Despite consistent earnings beats, stagnant revenue growth and bearish insider activity temper the outlook.
Compare Another Pair
Related Comparisons
DDS vs MUSA: Head-to-Head Comparison
This page compares Dillard's, Inc. (DDS) and Murphy USA Inc. (MUSA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.